


CLAIMS




What is claimed is:

1. A compound of structural Formula VII:



or a salt thereof, wherein

L is chosen from a bond and methylene;



R^{2c} is chosen from H, C₁-C₄alkoxy and C₃-C₄cycloalkoxy;

R^{2d} is chosen from null and C₁-C₄alkoxy;

R^{2e} is C₁-C₄alkyl;

n is 1 or 2 (forming an azetidin-1-yl or pyrrolidin-1-yl);


R^4 and R^5 are independently chosen from C₁-C₃alkyl; and

R^6 is chosen from H and C₁-C₄alkyl.

2. The compound as recited in claim 1, or a salt thereof, wherein W is


; R^4 and R^5 , together with the atoms to which they are attached, form a 3-7 membered cycloalkyl or heterocycloalkyl ring; and R^6 is chosen from H and C₁-C₄alkyl.

3. The compound as recited in claim 2, or a salt thereof, wherein n is 1, forming azetidin-1-yl.
4. The compound as recited in claim 3, or a salt thereof, wherein L is a bond.
5. The compound as recited in claim 1, wherein compound has structural Formula VIII:



or a salt thereof, wherein

L is chosen from a bond and methylene;



R^{2c} is chosen from H, C₁-C₄alkoxy and C₃-C₄cycloalkoxy;


R^{2d} is chosen from null and C₁-C₄alkoxy;


R^{2e} is C₁-C₄alkyl;


n is 1 or 2 (forming an azetidin-1-yl or pyrrolidin-1-yl);

R⁴ and R⁵ are independently chosen from C₁-C₃alkyl; and

R⁶ is chosen from H and C₁-C₄alkyl.




6. The compound as recited in claim 5, or a salt thereof, wherein Y is  ; R^{2c} is chosen from H, C₁-C₄ alkoxy and C₃-C₄ cycloalkoxy; and R^{2d} is chosen from null and C₁-C₄ alkoxy.
7. The compound as recited in claim 5, or a salt thereof, wherein n is 1, forming azetidin-1-yl.
8. The compound as recited in claim 7, or a salt thereof, wherein L is a bond.
9. The compound as recited in claim 8, or a salt thereof, wherein Y is




R^{2c} is chosen from H, C₁-C₄alkoxy and C₁-C₄cycloalkoxy; and

R^{2d} is chosen from null and C₁-C₄alkoxy.

10. The compound as recited in claim 1, wherein the compound has structural Formula XI:




or a salt thereof, wherein



m is 1, 2, or 3 (forming a cyclopropyl, cyclobutyl, or cyclopentyl);

L is chosen from a bond and methylene;



n is 1 or 2;

R⁴ and R⁵ are independently chosen from C₁-C₃alkyl;

R⁶ is chosen from H and C₁-C₄alkyl.


11. The compound as recited in claim 10, or a salt thereof, wherein W is

; R⁴ and R⁵, together with the atoms to which they are attached, form a 3-7 membered cycloalkyl or heterocycloalkyl ring; and R⁶ is chosen from H and C₁-C₄alkyl.

12. The compound as recited in claim 11, or a salt thereof, wherein L is a bond.

13. A compound of structural Formula VII as recited in claim 1 chosen from:





14. An isolated enantiomer of a compound as recited in claim 13 or a salt thereof.
15. A pharmaceutical composition comprising a compound as recited in any of claims 1–14, or a salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
16. A pharmaceutical composition comprising a compound as recited in any of claims 1–14 or a salt thereof for use in inhibiting activity of the monocarboxylate transporter MCT4, or a mutant thereof, in a biological sample comprising the step of contacting said biological sample with a compound as recited in any of claims 1-14, or a salt thereof.
17. A pharmaceutical composition comprising a compound as recited in any of claims 1–14 or a salt thereof for use in inhibiting activity of the monocarboxylate transporter MCT4, or a mutant thereof, in a patient.